Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.91 |
| ▸ | CASP1 | P29466 | 2/20 | 0.91 |
| ▸ | THRB | P10828 | 2/20 | 0.91 |
| ▸ | RAD52 | P43351 | 1/20 | 0.91 |
| ▸ | CASP7 | P55210 | 1/20 | 0.91 |
| ▸ | CASP6 | P55212 | 1/20 | 0.91 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.83 |
| ▸ | TP53 | P04637 | 2/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.83 |
| ▸ | PGR | P06401 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.83 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.83 |
| ▸ | NQO2 | P16083 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Primaquine SCHEMBL29576219 | 0.95 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL41097 | 0.95 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL41096 | 0.95 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL29409423 | 0.91 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL22208 | 0.91 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL12599100 | 0.91 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL22207 | 0.91 | KDM4E (1.00) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL979493 | 0.90 | KDM4E (0.98) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL6333949 | 0.90 | KDM4E (0.98) | KDM4ECASP1THRBRAD52CASP7 | |
| Primaquine SCHEMBL4959404 | 0.90 | KDM4E (0.98) | KDM4ECASP1THRBRAD52CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | claimed |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | UNIVERSITAT DE VALENCIA (ES) | 2014-01-02 | — | — | US | claimed |
| US-20250290076-A1 | EPICARDIAL CELL REGENERATION PROMOTER AND METHOD FOR PROMOTING EPICARDIAL CELL REGENERATION | KYOTO UNIVERSITY (JP) | 2025-09-18 | — | — | US | disclosed |
| EP-4516905-A1 | EPICARDIAL CELL REGENERATION PROMOTER AND METHOD FOR PROMOTING EPICARDIAL CELL REGENERATION | Kyoto University (JP) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023210713-A1 | EPICARDIAL CELL REGENERATION PROMOTER AND METHOD FOR PROMOTING EPICARDIAL CELL REGENERATION | 国立大学法人京都大学 | 2023-11-02 | — | — | WO | disclosed |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | FIBROSTATIN, S.L. (ES) | 2015-11-12 | — | — | US | disclosed |
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | disclosed |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | UNIVERSITAT DE VALENCIA (ES) | 2014-01-02 | — | — | US | disclosed |
| EP-2077113-A1 | Treatment of autoimmune diseases | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2009-07-08 | — | — | EP | disclosed |
| US-7105214-B2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20030124320-A1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-5657064-A | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5635322-A | Process for developing and overcoating migration imaging members | XEROX CORPORTION (US) | 1997-06-03 | — | — | US | disclosed |
| US-5580689-A | SOLFTENABLE LAYER OF SOFTENABLE MATERIAL, PIGMENT SENSITIVE TO INFRARED OR RED LIGHT ILLUMINATION, AND MIGRATION MARKING MATERIAL | XEROX CORPORATION (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5556743-A | COLORIMETRIC DETECTION AND QUANTITATIVE HYDROGEN PEROXIDE ANALYSIS | ACTIMED LABORATORIES, INC. (US) | 1996-09-17 | — | — | US | disclosed |
| US-5534374-A | Migration imaging members | XEROX CORPORATION (US) | 1996-07-09 | — | — | US | disclosed |
| EP-0673782-A2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| US-4530897-A | Process for desensitizing diazo lithographic printing forms using desensitizing solution with light absorbing compound | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | KDM4E 4163/4885CASP1 2498/4885THRB 2898/4885 |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | KDM4E 4163/4885CASP1 2498/4885THRB 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.